Summary. Rabbit anti-mouse tumour cell serum can be made tumour specific by absorption with normal mouse cells and in an in vivo protection test can be shown to have a measurable protective effect on mice against a given number of lethal doses of a lymphoma. Some drugs have been evaluated in this system. When drug treatment is combined with antibody treatment much greater protection can be obtained than when the same amounts of drug or antibody are used alone. It is preferable to administer drug before antibody and with the combined schedule it is possible in the test model to protect all mice from tumour growth, even allowing the tumour up to 48 h " get-away " time before starting treatment.
IN A previous paper (Davies, Manstone and Buckham, 1974b) we described some features of the protection of mice against leukaemias by using in vitro absorbed xeno-anti-tumour immunoglobulin; this particular design can be used to answer questions of clinical relevance because the reagent can be obtained in a similar way for human patients.
The test system is the protection of C57BL/6 mice against the carcinogen induced lymphoma EL4 with tumour specific immunoglobulin prepared from rabbit antiserum. This is a versatile system which has been used by many workers previously in various forms. It can be adjusted to greater sensitivity by (a) limiting the challenge dose of tumour cells, (b) reducing the time lapse between challenge and treatment and (c) giving multiple treatment doses of (d) greater amounts of putative therapeutic material. The test system can be made more severe by taking the reverse of any of these measures, as has been done for the tests described in this paper. Thus, for example, the amplification of the effect of antiserum treatment by drugs as described below has necessitated increasing the time lapse between challenge and treatment from 2 h to 96 h, otherwise protection would have been total and nothing learned about further possible improvements.
Tumour specific antibodies alone are not able to reverse the continuing growth of well established tumours in clinical practice, but our results (Davies and O'Neill, 1973; Davies et al., 1974b) hinted at a synergistic effect between drugs and antibodies. This topic is expanded upon in the present paper, because the combined effect might be capable of tipping the balance in a patient's favour.
MATERIALS AND METHODS
Biological.-These were described in some detail in our previous paper (Davies et al., 1974b) and can be summarized as follows. Rabbits were immunized by 3 injections at 10 day intervals of 108 live EL4 cells (grown in C57BL/6 mice) and bled 10 days later. (Davies and O'Neill, 1973 The " DRAB " (drug-antibody) effect Cyclophosphamide. The test illustrated in Fig. 2 shows that an amount of cyclophosphamide able to give a measurable degree of prolongation of life with a time lapse (between challenge and treatment) of 18 h ( Fig. 1 ) gives no effect if the time lapse is increased to 96 h. An amount of antibody was given which also showed no effect alone (this was calculated from data obtained in previous experiments). When the same dose of drug was followed an hour later by the same dose of antibody, other possible variables being held constant, there was a modest but very definite protective effect.
Chlorambucil.-When chlorambucil was used at a comparable " safe " dose, the same kind of effect was obtained and is shown in Fig. 3 serum (Fig. 4) with (1rg doses straddliing the 0-2 mg used in the previous test. Melphalan. When melphalan was uise(I at the " safe " dose of 20 ,ug and with a 48 h time lapse, but otherwise under the same conditions as the previous tests, the amplification over a very modest effect of drug or antibody alone was so marked that all mice in that group survived to a normal life span with no tumour growth (Fig. 5) (Boyle, Davies and Haughton, 1963; Haughton, 1962) . In a protection test (not illustrated), this serum gave no protective effect to C57BL/6 mice against EL4 under conditions where R 140 (an antiserum against EL4) showed a substantial effect. A sub-protective dose of chlorambucil gave a negligible effect but amplified that of serum R140. Drug followed by anti-CEA had no effect (identical with normal rabbit serum controls), showing that anti-CEA is not able to collaborate in a DRAB effect. Order and timing. When EL4 Ig was uised fullY absorbed at a of 4 mg/mouse, and chlorambuc 2 dose levels, 0-1 and 0 2 mg, t preparations were given in the drug-l h-antibody, and antibodydrug. It will be seen from F that in both comparable pairs of g of mice, the order druig-antibody i more effective one.
The effect of absorption. A bat anti-EL4 rabbit serum was absort times and samples kept from each The cytotoxicity titres are show Fig. 7 using normal C157BL/6 lyn cytes and it can be seen that no reac remnained after the thirdl absorl xenodose il at the 2 order -1 hig. 6 ;roups is the there was, of course, residuial activity for EL4 target cells. WTheni these sera were tested for their protective capacity in vivo, the results showed clearly that absorption greatly affected the issue when the total amouint of seruim given to each grouip of mice was the same (Fig. 8) .
DISCUSSION
The resuilts given in this paper are ch of examples taken from an exteinsive series )ed 3 of protection tests which serve to show a stage. novel finding that a cytotoxic drug Krn in followed by a tumour specific antibody npho-provides treatment far more effective tivity than can be achieved with either alone ?tion; (DRAB effect). The best combined effect was obtained with the drugs which were most effective alone, in the order melphalan, chlorambucil, cyclophosphamide. In the least effective situation of cyclophosphamide, and with a time lapse of 96 h between challenge and treatment, the DRAB effect was clear (Fig. 2 (Ghose et al., 1972) but the effects claimed are likely to be due to the DRAB effect we now describe (see Davies and O'Neill, 1 973; O'Neill, Pearson and Davies, 1974) . A slight buit measurable benefit found with (Irug an(i normal rabbit serum may be due to the direct toxicity of most rabbit sera for mice. In any event, wTith tumour antisera a (legree of specificity for effects on tumour cells rather than host cells is evident, and presumably follows on the absorption of antibody against normal tissue. This very laborious absorption has a further and unexpected influence, in that the effectiveness of DRAB is very much dependent on this absorption (Fig. 8) and therefore some interference with protection results from the presence of antibody against normal mouse tissues.
The tests using antibody one hour after drug administration have had the most favourable outcome but a series of protection tests designed to clarify the ideal sequence and timing have given some confusing results and will be reported on when better clarified.
From the practical point of view, it is important to discover what kind of antigens expressed by tumours are candidates for production of antibody to obtain a DRAB effect. We have taken advaintage of the tumour specific antigen of EL4 cells (Gorer and Amos, 1956) which is the cell surface expressed character distinguishing this carcinogen induced lymphoma from its host's tissues (Davies, 1963; Davies et al., 1974a) . This suggests that for human patients a serum may need to be raised for each individual. On the other hand, cross-reactions are well known between tumours in certain classes. Thus for example, a series of goat anti-human melanoma sera, after full absorption with human spleens until non-cytotoxic for normal human lymphocytes, reacted with cells of a cultured human melanoma cell line (O'Neill, to be published). Whether such a crossreactive antibody would serve to take part in a DRAB effect remains to be seen, but using the more widely crossreacting mouse CEA (carcinoembryonic antigen) as immunogen, the strongly reactive antiserum remaining after absorption with normal tissue failed to show any collaboration with chlorambucil in protection of mice against their syngeneic tumour.
